We Are Alessa
Our team has significant experience in creating advanced therapeutic approaches in the lab – and transitioning them to the clinic. We came together at the UCSF Department of Hematology/Oncology, and have recruited experienced industry professionals to develop and commercialize our technology.
We are all motivated by a shared goal: to create innovative advancements in oncology and treatment of solid organ diseases.
Alessa is currently conducting their first in-man clinical study of Biolen® PC, a minimally invasive, implantable drug delivery system for patients with localized non-metastatic prostate cancer. Biolen PC is designed to administer anti-androgen drugs to the tumor in the prostate through a sustained, localized system – without systemic exposure.
- Alessa Therapeutics Announces First Patient Enrollment in Biolen®+RT Study with National Cancer InstituteAlessa Therapeutics Announces First Patient Enrollment in Biolen®+RT Study with National Cancer Institute SAN CARLOS, CALIFORNIA, US, February 23, 2022 /EINPresswire.com/ Alessa Therapeutics, Inc., … Read more
- Alessa Therapeutics Announces Research Collaboration with JanssenAlessa Therapeutics Announces Research Collaboration with Janssen SAN CARLOS, CALIFORNIA, US, October 11, 2021 /EINPresswire.com/ Alessa Therapeutics, Inc., a clinical-stage drug development company developing … Read more